Clinical impact of SGLT2 inhibitor after DC cardioversion in persistent atrial fibrillation patients with heart failure with preserved ejection fraction

Clinical impact of SGLT2 inhibitor after DC cardioversion in persistent atrial fibrillation patients with heart failure with preserved ejection fraction: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0009157

Enrollment

200

Registered

2024-02-01

Start date

2024-01-01

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : In patients with persistent atrial fibrillation, if the subjects are eligible, the subjects will be randomly allocated to the SGLT2 inhibitor group and the control group at a 1:1 ratio after st

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Patients aged 19 or more ? Patients with persistent atrial fibrillation ? H2FPEF diagnostic criteria of 6 or more or HFA-PEFF diagnostic criteria of 5 or more ? Patients who have converted to sinus rhythm after DC cardioversion

Exclusion criteria

Exclusion criteria: ? Patients who used SGLT2 inhibitors in the past ? Patients with less than 45 creatinine clearance ? Patients with intracardiac thrombus confirmed by transesophageal echocardiography ? Patients who refused to participate in the study

Design outcomes

Primary

Measure	Time frame
atrial tachyarrhythmia (atrial fibrillation, atrial flutter, atrial tachycardia) recurrence	—

Secondary

Measure	Time frame
recurrence of atrial fibrillation;recurrence of atrial flutter;recurrence of atrial tachycardia;All-cause death;Cardiac death;stroke;Blood test results (BUN, creatinine, electrolyte, NTproBNP);drug-related side effects;patient quality of life (EHRA score, AFEQT score)	—

Countries

Korea, Republic of

Contacts

Public ContactMinjeong Kwon

Samsung Medical Center

gms06261@naver.com+82-2-2148-7611

Outcome results